{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:06:16Z","timestamp":1788185176869,"version":"build-2803163510"},"reference-count":26,"publisher":"Informa UK Limited","issue":"14","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.2217\/fon-2023-0604","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T10:03:22Z","timestamp":1704881002000},"page":"935-950","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed\/refractory myeloma in routine practice"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-4170","authenticated-orcid":false,"given":"Xavier","family":"Leleu","sequence":"first","affiliation":[{"name":"P\u00fale R\u00e9gional de Canc\u00e9rologie, Department of Hematology, CHU La Mil\u00e9trie-Poitiers, Poitiers, 86000, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C","family":"Lee","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center, Houston, TX77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Zonder","sequence":"additional","affiliation":[{"name":"Barbara Ann Karmanos Cancer Institute\/Wayne State University School of Medicine, Detroit, MI48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[{"name":"CHU de Caen, Caen, 14000, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, OX3 7LE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Bordeaux, 33000, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Silar","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matyas","family":"Kuhn","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaili","family":"Ren","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA), Lexington, MA02421, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawal","family":"Bent-Ennakhil","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Opfikon, 8152, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasha","family":"Cherepanov","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA), Lexington, MA02421, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn Marie","family":"Stull","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA02421, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National & Kapodistrian University of Athens, School of Medicine, Athens,115 27, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"e_1_3_10_3_1","unstructured":"Takeda Pharmaceuticals America Inc. Lexington MA USA . NINLARO\u00ae US prescribing information. (Revised 5\/2022). www.ninlaro.com\/prescribing-information.pdf (Accessed 23August2022)."},{"key":"e_1_3_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_3_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"e_1_3_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.625"},{"key":"e_1_3_10_7_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1225"},{"key":"e_1_3_10_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07732-1"},{"key":"e_1_3_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03981-z"},{"key":"e_1_3_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05278-3"},{"key":"e_1_3_10_11_1","first-page":"463","article-title":"Real-world duration of treatment (DOT) with lenalidomide-dexamethasone (Rd)-based regimens in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): outcomes from the global INSIGHT MM study","volume":"5","author":"Puig N","year":"2021","unstructured":"Puig N , AbonourR , DaviesFEet al. Real-world duration of treatment (DOT) with lenalidomide-dexamethasone (Rd)-based regimens in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): outcomes from the global INSIGHT MM study. HemaSphere5, 463 (2021). (Abstract EP985).","journal-title":"HemaSphere"},{"key":"e_1_3_10_12_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0013"},{"key":"e_1_3_10_13_1","first-page":"468","article-title":"Effectiveness and safety of ixazomib-based therapy in relapsed\/refractory multiple myeloma (MM) outside of a clinical trial: final analysis of the \u2019use via early access to ixazomib\u2019 (UVEA IXA) study","volume":"5","author":"Ludwig H","year":"2021","unstructured":"Ludwig H , TerposE , MateosM-Vet al. Effectiveness and safety of ixazomib-based therapy in relapsed\/refractory multiple myeloma (MM) outside of a clinical trial: final analysis of the \u2019use via early access to ixazomib\u2019 (UVEA IXA) study. HemaSphere5, 468 (2021). (Abstract EP994).","journal-title":"HemaSphere"},{"key":"e_1_3_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150150"},{"key":"e_1_3_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187"},{"key":"e_1_3_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0539-0"},{"key":"e_1_3_10_17_1","first-page":"1818","article-title":"Duration of therapy (DOT) and time to next therapy (TTNT) of bortezomib, carfilzomib and ixazomib combinations with lenalidomide\/dexamethasone (VRd, KRd, IRd) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): clinical practice in the United States vs clinical trial experience","volume":"130","author":"Chari A","year":"2017","unstructured":"Chari A , RomanusD , LuptakovaKet al. Duration of therapy (DOT) and time to next therapy (TTNT) of bortezomib, carfilzomib and ixazomib combinations with lenalidomide\/dexamethasone (VRd, KRd, IRd) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): clinical practice in the United States vs clinical trial experience. Blood130, 1818 (2017).","journal-title":"Blood"},{"key":"e_1_3_10_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e19135"},{"key":"e_1_3_10_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2023.2208439"},{"key":"e_1_3_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-019-00607-2"},{"key":"e_1_3_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213"},{"key":"e_1_3_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.12.012"},{"key":"e_1_3_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23933"},{"key":"e_1_3_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2901-x"},{"key":"e_1_3_10_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08881-7"},{"key":"e_1_3_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0805-y"},{"key":"e_1_3_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.005"},{"key":"e_1_3_10_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1729734"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T14:29:50Z","timestamp":1726756190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":26,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.2217\/fon-2023-0604"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0604","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}